HomeCompareNMFCL vs MRK

NMFCL vs MRK: Dividend Comparison 2026

NMFCL yields 12.89% · MRK yields 2.76%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 MRK wins by $3.1K in total portfolio value· pulled ahead in Year 10
10 years
NMFCL
NMFCL
● Live price
12.89%
Share price
$25.26
Annual div
$3.26
5Y div CAGR
3.1%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$53.7K
Annual income
$4,382.25
Full NMFCL calculator →
MRK
Merck & Co. Inc.
● Live price
2.76%
Share price
$120.31
Annual div
$3.32
5Y div CAGR
32.7%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$56.8K
Annual income
$9,798.13
Full MRK calculator →

Portfolio growth — NMFCL vs MRK

📍 MRK pulled ahead of the other in Year 10

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodNMFCLMRK
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, NMFCL + MRK cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
NMFCL pays
MRK pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

NMFCL
Annual income on $10K today (after 15% tax)
$1,095.31/yr
After 10yr DRIP, annual income (after tax)
$3,724.91/yr
MRK
Annual income on $10K today (after 15% tax)
$234.56/yr
After 10yr DRIP, annual income (after tax)
$8,328.41/yr
At 15% tax rate, MRK beats the other by $4,603.50/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of NMFCL + MRK for your $10,000?

NMFCL: 50%MRK: 50%
100% MRK50/50100% NMFCL
Portfolio after 10yr
$55.2K
Annual income
$7,090.19/yr
Blended yield
12.84%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on MRK right now

NMFCL
No analyst data
MRK
Analyst Ratings
25
Buy
11
Hold
1
Sell
Consensus: Buy
Price Target
$128.54
+6.8% upside vs current
Range: $100.00 — $150.00
Altman Z
4.0
Piotroski
6/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

NMFCL buys
0
MRK buys
0
No recent congressional trades found for NMFCL or MRK in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricNMFCLMRK
Forward yield12.89%2.76%
Annual dividend / share$3.26$3.32
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR3.1%32.7%
Portfolio after 10y$53.7K$56.8K
Annual income after 10y$4,382.25$9,798.13
Total dividends collected$26.5K$28.9K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: NMFCL vs MRK ($10,000, DRIP)

YearNMFCL PortfolioNMFCL Income/yrMRK PortfolioMRK Income/yrGap
1$12,029$1,328.55$11,206$366.19+$823.00NMFCL
2$14,410$1,539.80$12,650$502.35+$1.8KNMFCL
3$17,197$1,777.46$14,407$694.19+$2.8KNMFCL
4$20,444$2,043.82$16,585$967.82+$3.9KNMFCL
5$24,216$2,341.23$19,342$1,363.89+$4.9KNMFCL
6$28,584$2,672.15$22,913$1,947.19+$5.7KNMFCL
7$33,624$3,039.10$27,662$2,823.89+$6.0KNMFCL
8$39,422$3,444.65$34,159$4,173.35+$5.3KNMFCL
9$46,073$3,891.47$43,337$6,308.80+$2.7KNMFCL
10← crossover$53,680$4,382.25$56,776$9,798.13$3.1KMRK

NMFCL vs MRK: Complete Analysis 2026

NMFCLStock

New Mountain Finance Corporation is a Business Development Company specializing in investments in middle market companies and debt securities at various levels of the capital structure, including first and second lien debt, unsecured notes, bonds, and mezzanine securities. It invests in various industries that include software, education, business services, distribution and logistics, federal services, healthcare services and products, healthcare facilities, energy, media, consumer and industrial services, healthcare Information Technology, Information Technology and services, specialty chemicals and materials, telecommunication, retail, and power generation. It seeks to invest in United States. It typically invests between $10 million and $50 million. Within middle market it seeks to invest in companies having EBITDA between $20 million and $200 million. It prefers to invest in equity interests, such as preferred stock, common stock, warrants, or options received in connection with its debt investments and directly in the equity of private companies. The fund makes investments through both primary originations and open-market secondary purchases. It invests primarily in debt securities that are rated below investment grade and have contractual unlevered returns of 10% to 15%. The firm may also invest in distressed debt and related opportunities and prefers to invest in targets having private equity sponsorship. It seeks to hold its investments between five years and ten years. The fund prefer to have majority stake in companies.

Full NMFCL Calculator →

MRKHealthcare

Merck & Co., Inc. operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, and diabetes, as well as vaccine products, such as preventive pediatric, adolescent, and adult vaccines. The Animal Health segment discovers, develops, manufactures, and markets veterinary pharmaceuticals, vaccines, and health management solutions and services, as well as digitally connected identification, traceability, and monitoring products. It serves drug wholesalers and retailers, hospitals, and government agencies; managed health care providers, such as health maintenance organizations, pharmacy benefit managers, and other institutions; and physicians and physician distributors, veterinarians, and animal producers. The company has collaborations with AstraZeneca PLC; Bayer AG; Eisai Co., Ltd.; Ridgeback Biotherapeutics; and Gilead Sciences, Inc. to jointly develop and commercialize long-acting treatments in HIV. Merck & Co., Inc. was founded in 1891 and is headquartered in Kenilworth, New Jersey.

Full MRK Calculator →
📬

Get this NMFCL vs MRK comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

NMFCL vs SCHDNMFCL vs JEPINMFCL vs ONMFCL vs KONMFCL vs MAINNMFCL vs JNJNMFCL vs ABBVNMFCL vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.